CLP-[ZIP_CODE].D CONFIDENTIAL  Page 1 of 45 STRIDE : A Study of Patients with Lower Extremity Acute 
Limb Ischemia to Remove Thrombus with the I ndigo® 
Aspi[INVESTIGATOR_820539]-[ZIP_CODE].D 
Date of P
rotocol 
05/20/2021 
Device Na
me 
Indigo® Aspi[INVESTIGATOR_820540], Inc.  
One Penumbra Place  
Alameda, CA [ZIP_CODE] 
[LOCATION_003] 

CLP-[ZIP_CODE].D CONFIDENTIAL  Page 2 of 45 
 TABLE OF CONTENTS  
1 Introduction and Rationale  .................................................................................................. 7  
 Disease State and Prevalence  ........................................................................................................ 7 
 Current Treatments  ................................................................................................ ....................... 7  
2 Device Description  ................................................................................................................ 8  
 Indigo® Aspi[INVESTIGATOR_228483]  ................................................................................................ ............ 8  
 Indigo Aspi[INVESTIGATOR_820541]  ................................................................ ............... 9  
 Indigo® Aspi[INVESTIGATOR_228483], CAT RX Aspi[INVESTIGATOR_820542], and SeparatorTM 4 .................... 10  
 Aspi[INVESTIGATOR_477100]  ........................................................................................................................ 11  
 Penumbra Aspi[INVESTIGATOR_448982]  ....................................................................................................... 11  
 Penumbra Aspi[INVESTIGATOR_820543] ........................................................................................ 11  
3 Risk Analysis  ....................................................................................................................... 12  
 Risks Related to Aspi[INVESTIGATOR_820544]  ............................................................................. 12  
4 Study Overview  ................................................................................................................... 13  
 Study Design  ................................................................................................................................. 13  
 Study Objectives/Endpoints  ........................................................................................................ 14  
4.2.1  Prima
ry Endpoints  .............................................................................................................. 14 
4.2.2  Secondary Endpoints  .......................................................................................................... 14 
5 Study Population ................................................................................................................. 14  
 Inclusion Criteria  ......................................................................................................................... 14  
 Exclusion Criteria  ........................................................................................................................ 14  
6 Study Procedures  ................................................................................................................ 15  
 Overview of Study Flow .............................................................................................................. 15  
 Study Visits  ................................................................................................................................... 17  
 Recruitment and Screening  ......................................................................................................... 17  
 Enrollment  .................................................................................................................................... 17  
 Informed Consent  ........................................................................................................................ 17  
 Baseline Evaluation ...................................................................................................................... 18  
 Procedure  ...................................................................................................................................... 19  
6.7.1  Prepara
tion for Treatment ................................................................................................. 19 
6.7.2  Medication during Intervention  ......................................................................................... 19 
6.7.3  Devices and Equipment  ...................................................................................................... 19 
6.7.4  Index Procedure  .................................................................................................................. 21 
6.7.5  Discharge and/or [ADDRESS_1137256]  .............................................................. 21 
6.7.6  30 Day Follow Up Visit (± 14 days)  .................................................................................... 22 
6.7.7  180 Day Follow Up Visit (± 30 days)  .................................................................................. 22 
6.7.8  365 Day Follow Up Visit (± 60 days)  .................................................................................. [ADDRESS_1137257] / Ethics Committee Approval  ....................................................... 24  
 Informed Consent  ........................................................................................................................ 24  
 Adherenc e to Protocol/Amendments and Applicable Law  ...................................................... [ADDRESS_1137258] Data Protection ............................................................................................................... 31  
10 Statistical Procedures  ......................................................................................................... 31  
 General Statistical Considerations  ............................................................................................. 31  
 Sample Size Estimation for the Primary Outcome  ................................................................... 31  
 Control of Systematic Error and Bias  ........................................................................................ 31  
 Missing Data and Imputation Methods  ..................................................................................... 31  
 Definition of Populations  ............................................................................................................. 32  
10.5.1  Screened  
............................................................................................................................... 32 
10.5.2  Screen Failure  ...................................................................................................................... 32 
10.5.3  Enrol led ................................................................................................................................ 32 
10.5.4  Completed  ............................................................................................................................ 32 
10.5.5  Early Termination  ............................................................................................................... 32 
 Definition of Analysis Populations  ............................................................................................. 32  
10.6.1  Inten
t to Treat Sample  ........................................................................................................ 32 
 Interim Analysis  ........................................................................................................................... 32  
 Statistical Analysis of Primary Endpoint ................................................................................... 33  
 Secondary Statistical Analysis  .................................................................................................... 33  
 Analysis of Adverse Events  ..................................................................................................... 33  
 Baseline Characteristics  .......................................................................................................... 33  
 Pooling Across Centers  ........................................................................................................... 33  
 Final Report  ............................................................................................................................. 34  
11 Study Committees and Core Labs  ..................................................................................... 34  
 Imaging Core Lab ........................................................................................................................ 34  
12 Study Administration ......................................................................................................... 34  
 Stoppi[INVESTIGATOR_820545]  .................................................................... 34  
 Clinical Study Termination/Withdrawal  ................................................................................... [ADDRESS_1137259] Information ........................................................................................................... 37  
15 References  ............................................................................................................................ 38  
16 APPENDIX I: Definitions and Classifications  ................................................................. 40  
 Definitions  ..................................................................................................................................... 40  
 Acronyms ...................................................................................................................................... 41  
17 APPENDIX II: Classifications and Scales ........................................................................ [ADDRESS_1137260] Classification for Acute Limb Ischemia 18, 19 ......................................................... 42  
 Fontaine Classification 18 ............................................................................................................. 42  
CLP-[ZIP_CODE].D CONFIDENTIAL  Page 4 of 45 
 
 Modified SVS Runoff Score 20 ..................................................................................................... 43  
 TASC II Aortoiliac Lesion Classification 20 ............................................................................... 43  
 TASC II Femoral -Popliteal Lesion Classification 20 ................................................................. 44  
 TIMI Flow 21 ................................................................................................................................. 44  
 Vascular Quality of Life – 6 22 ..................................................................................................... 45  
 
  
CLP-[ZIP_CODE].D CONFIDENTIAL  Page 7 of 45 
 1 Introduction and Rationale  
 Disease State and Prevalence  
Acute limb ischemia (ALI)  is a vascular emergency characterized by a sudden loss of 
arterial perfusion in the lower limbs .1-3 The condition affe cts an estimated 15 -26 patients 
/ 100,000 persons / yr in the [LOCATION_002]1, and is associated with extremely high 
morbidity and mortality rates. In the  [LOCATION_006], a  study calculated an annual ALI incidence of 
10 in 100,000, with 5-year survival rates for avoiding amputation at 36.7% and overall 
at 55.9%.4  
Mortality at 1  yr can reach 40%1, [ADDRESS_1137261] -procedur al rates of limb loss are reported in 
between 12% -50% of cases.5 Optimal clinical outcomes therefore necessitate urgent 
recognition of the condition and prompt restoration of arterial blood flow, in order  to 
avoid irreversible ischemia and to support limb salvage.2, 3  
In ALI, the rapid onset of perfusion limitation (<14 days) threatens limb viability due to 
insufficient time for adequate collateral  recruitment.6 Clinical diagnosis depends on 
symptom presentation, which includes the ‘6P’s’: pain, pallor, pulse deficit, paresthesia, poikilothermia, and paralysis of the affected limb.
6, [ADDRESS_1137262] been no significant 
improvements in 1-yr amputation-free survival, which remains unchanged at 52.3%.1, [ADDRESS_1137263] category II (a and b) are at risk of limb 
loss, with prompt treatment and revascularization urgently indicated for limb salvage.  Contemporary revascularization guidelines for ALI include, but are not limited to, catheter -directed thrombolysis  (CDT), percutaneous thrombo- aspi[INVESTIGATOR_1516], and surgical 
thromboembolectomy.
2, [ADDRESS_1137264] decades, the surgical management of ALI has 
evolved to include endovascular approaches,5, 9 especially following the publication of 
three randomized, multicenter trials which established the efficacy of catheter -directed 
thrombolysis (CDT) as compared with surgical revascularization.10-[ADDRESS_1137265] in assessing the efficacy of different revascularization devices and 
procedures.14  
 The PEARL registry evaluated 283 patients (mean ag e 65±13years) from 34 institutions 
across the US which tracked the use of rheolytic pharmacomechanical thrombectomy (PMT) to manage ALI.
9 This method generates low -pressure suction to remove occlusive 
lesions. At 12- month follow -up, amputation- free survival and freedom from mortality 
was 81% and 91%, respectively. This study supported the use of PMT, as a first -line 
CLP-[ZIP_CODE].D CONFIDENTIAL  Page 8 of 45 
 treatment for ALI, with reduced procedure times and an acceptable risk profile compared 
with CDT .9 
 
Although CDT remains an established technique for ALI treatment, it can be associated 
with multiple procedures and hemorrha gic complications.15 A small 2018 study 
comparing percutaneous aspi[INVESTIGATOR_675520] (PAT) (n=15) versus conventional CDT (n=27) in treating noniatrogenic acute lower limb ischemia, found that first -line use 
of PAT for endovascular treatment of ALI could reduce the need for CDT, without significantly increasin g costs.
15  
 PRISM, a multicenter retrospective case analysis , was established  to determine the safety 
and initial efficacy of another aspi[INVESTIGATOR_1516] –based extraction technique  (XTRACT ), for 
treating  peripheral arterial thromboembolism  using  the Penumbra/  Indigo S ystem .
16 
Seventy -nine patients (median age 69 years  [IQR], 60 –78 years) with peripheral 
occlusions were enrolled treated with XTRACT as the initial therapy or secondary therapy. Complete or near -complete revascularization (TIMI grade 2/3) was achieved in 
79.5% of patients who received Indigo as a frontline treatment and successful 
revascularization was achieved in 92.5% of patients who received aspi[INVESTIGATOR_1516]- based 
therapy as salvage or secondary therapy.
16 Complete flow restoration (TIMI grade 3) was 
successfully achieved in 77.2% of patients, and no patients required surgical revascularization. No device- related ad verse events occurred, establishing the safety and 
efficacy of using the Penumbra/  Indigo system for aspi[INVESTIGATOR_1516] -based extraction of acute 
peripheral arterial occlusions .
[ADDRESS_1137266] I, IIa and IIb categories, for whom immediate 
treatment and revascu larization can maintain limb viability and prevent limb loss.  Rapid 
restoration of arterial flow is crucial. The FRIENDS registry (n=200) showed that delays in treatment of limb ischemia is associated with poorer outcomes in ALI patients, including much higher rates of first amputation (p=0.0002) and worse amputation- free 
survival rates (p<0.05) .
[ADDRESS_1137267] burden and poor clinical outcomes 
associated with ALI, this registry will provide much -needed clinical data on restoring 
vessel patency and improving patient morbidity and mortality rates.  
 
2 Device Description  
 Indigo® Aspi[INVESTIGATOR_820546]/Overview 
The Indigo Aspi[INVESTIGATOR_820547]: 
• Indigo Aspi[INVESTIGATOR_672211]  
• Penumbra Aspi[INVESTIGATOR_448982] 
• Indigo Pump/Canister Tubing • Indigo Aspi[INVESTIGATOR_477100] • Indigo Separator™  
 
CLP-[ZIP_CODE].D CONFIDENTIAL  Page 9 of 45 
 The Indigo Aspi[INVESTIGATOR_820548]. The Indigo Aspi[INVESTIGATOR_820549]. T he Indigo Separator may be used  to clear the lumen of the 
Indigo Aspi[INVESTIGATOR_820550]. The use of the I ndigo 
Separator may not be necessary when using an I ndigo Aspi[INVESTIGATOR_820551] I.D.  of 
0.054 in [1.37 mm] or larger. The Indigo Aspi[INVESTIGATOR_820552] a guide 
catheter or introducer sheath and into the peripheral  vasculature and guided over a 
guidewire to the site of the primary occlusion. The Indigo Aspi[INVESTIGATOR_820553]. As needed, 
an Indigo Separator  may be deployed from the Indigo Aspi[INVESTIGATOR_820554]. The Indigo Separator is advanced and retracted through the  Indigo 
Aspi[INVESTIGATOR_820555]. For  the aspi[INVESTIGATOR_820556], the 
Indigo Aspi[INVESTIGATOR_820557], 
which is connected using the Indigo Aspi[INVESTIGATOR_820558]/Canister 
Tubing. The Indigo Aspi[INVESTIGATOR_820559] a steam shapi[INVESTIGATOR_820560], and a peelable sheath. The Indigo Separator is provided  with 
an introducer and torque device. The devices are visible under fluoroscopy.  
 
The Indigo Aspi[INVESTIGATOR_820561] (FDA) 
510(k) clearance for the peripheral arterial indication in September 2012 under K121917. 
In May 2015 under K142870 the indication was expanded to the peripheral arterial and 
venous indication and is currently available in the [LOCATION_002]. The Indigo Aspi[INVESTIGATOR_820562] 18 September 2014 under Registration Numbe r 
252.943 and is currently available in Europe.  
 Indigo Aspi[INVESTIGATOR_820563], the Indigo Aspi[INVESTIGATOR_820564], soft emboli and thrombi from vessels  of the 
peripheral arterial and venous systems.   Indigo Aspi[INVESTIGATOR_820565]. The Aspi[INVESTIGATOR_820566] a kit with the Aspi[INVESTIGATOR_477100]. The kit also 
contains a rotating hemostasis valve (RHV) and an introducer sheath.   
 
Figure 1: Assembled Aspi[INVESTIGATOR_820567]-[ZIP_CODE].D CONFIDENTIAL  Page 10 of 45 
  
 Indigo® Aspi[INVESTIGATOR_228483], CAT RX Aspi[INVESTIGATOR_672211], and SeparatorTM 4 
As part of the INDIGO Aspi[INVESTIGATOR_228483], the INDIGO CAT RX Aspi[INVESTIGATOR_820568] 4 are indicated for the removal of fresh, soft emboli and thrombi from vessels in the coronary and peripheral vasculature. 
 
General Description/Overview  
The Indigo™ Aspi[INVESTIGATOR_820547], which will be available 
based on applicable regulatory approvals for commercialization: 
• Indigo CAT RX Aspi[INVESTIGATOR_672211] • Indigo Separator™ 4 • Indigo Aspi[INVESTIGATOR_477100] • Indigo Pump Canister/Tubing • Penumbra Aspi[INVESTIGATOR_820569]. The Indigo CAT RX Aspi[INVESTIGATOR_820570] a dual lumen rapid exchange catheter that targets aspi[INVESTIGATOR_820571], removing it via the Indigo Aspi[INVESTIGATOR_820572]. The Indigo Separator 4 may be used, if needed, to clear the lumen of the Indigo CAT RX Aspir ation Catheter should it become blocked with thrombus. The Indigo CAT RX 
Aspi[INVESTIGATOR_820573] a guide catheter or long introducer sheath into the coronary or peripheral vasculature and guided over a guidewire to the site of the 
primary  occlusion. The Indigo CAT RX Aspi[INVESTIGATOR_820574] a 
rotating hemostasis valve and a peelable sheath. The Indigo Separator 4 is provided with an introducer and torque device. The Indigo CAT RX Aspi[INVESTIGATOR_820575] 4 are visible under fluoroscopy.  
 The Indigo CAT RX Aspi[INVESTIGATOR_672211], including the Separator 4 and the Aspi[INVESTIGATOR_477100], received US Food and Drug Administration (FDA) 510(k) clearance in May 2017 
under K163618 and is currently available in the [LOCATION_002].   The Indigo CAT RX Aspi[INVESTIGATOR_672211], including the Separator 4 and the Aspi[INVESTIGATOR_820576].  
 
Figure 2: Assembled Aspi[INVESTIGATOR_820577] [ADDRESS_1137268] the Indigo Aspi[INVESTIGATOR_820578].  
 
Lightning Aspi[INVESTIGATOR_820579] , 
which received original US Food and Drug Administration (FDA) 510(k) clearance in 
March [ADDRESS_1137269] received appropriate training in surgical procedures and/or interventional techniques. 
 
During scenarios when occlusion is detected (e.g. blood clot is engaged with an Indigo Aspi[INVESTIGATOR_672211]), Lightning allows for continuous aspi[INVESTIGATOR_820580]. During scenarios when no occlusion is detected, Lightning is designed to minimize aspi[INVESTIGATOR_820581].   Consistent with the existing Indigo Aspi[INVESTIGATOR_477100], the operator/physician will be able to maintain manual control of flow via a flow control switch which will completely stop flow when in the “OFF” position.  
Figure 2: Lightn ing Aspi[INVESTIGATOR_820582] a vacuum source for Penumbra Aspi[INVESTIGATOR_820583].  
 
 Penumbra Aspi[INVESTIGATOR_820584]-[ZIP_CODE].D CONFIDENTIAL  Page [ADDRESS_1137270] the Pump to the Pump 
Canister. This tubing has an inline filter to prevent fluid and contaminants from entering the pump. The tubing lumen remains open under full vacuum. The Penumbra ENGINE 
does not require this additional tubing. The Suction Connector is securely attached to the Pump Canister lid and Pump via press fit.  Further detailed description of all the devices listed in this protocol can be found within their respective Instructions For Use ( IFU).  
 
3 
 Risk Analysis 
A thorough risk analysis was performed as part of design control requirements of the Quality 
System Regulation (21 CFR 820)  and r isk management activities were performed in 
accordance with ISO [ZIP_CODE] 
 Risks Related to Aspi[INVESTIGATOR_820585], soft emboli and thrombi from vessels of the peripheral arterial and venous systems are unchanged since market introduction. In terms of the 
clinical risk, adverse events that may be associated with the use of the Indigo Aspi[INVESTIGATOR_820586], but may not be limited to: 
 
• allergic reaction and anaphylaxis   from contrast media  
• acute occlusion • air embolism • arteriovenous fistula • death  
• device malfunction  
• distal embolization  
• emboli • false aneurysm formation  
• hematoma or hemorrhage at access site  
• inability to completely remove thrombus • infection •  hemorrhage •  ischemia  
•  kidney damage from contrast media •  neurological deficits including stroke •  vessel spasm, thrombosis, dissection, or perforation •  intimal disruption  
CLP-[ZIP_CODE].D CONFIDENTIAL  Page 13 of 45 
 •  myocardial infarction  
•  emergent surgery  
•  fibrillation  
•  hypotension 
•  respi[INVESTIGATOR_1399]  
•  peripheral thromboembolic events 
 
Risks that may be associated with the Lightning Aspi[INVESTIGATOR_1516] T ubing include, but may not be 
limited to:  
• allergic reaction and anaphylaxis from contrast media  
• acute occlusion  
• air embolism 
• arrhythmia/fibrillation  
• arteriovenous fistula  
• death  
• device m alfunction  
• distal embolization  
• emergent surgery  
• false aneurysm formation  
• hematoma, hemorrhage, or blood loss at access site  
• hematoma, hemorrhage, or blood loss  
• hypotension 
 • inability to completely remove 
thrombus or control blood flow 
• infection  
• ischemia  
• kidney damage from contrast 
media  
• myocardial infarction  
• neurological deficits including 
stroke 
• respi[INVESTIGATOR_1399]  
• thromboembolic events 
• vascular complications (including vessel spasm, thrombosis, intimal disruption, dissection, or perforation) 
 
 Considerable testing has been completed to ensure that the Indigo Aspi[INVESTIGATOR_820587] a significant risk. Safety of the Indigo Aspi[INVESTIGATOR_820588] -clinical test ing in both bench- top and in vivo models. Critical 
design characteristics were evaluated to ensure that system components can withstand the rigor of clinical use. A thorough risk analysis was performed as part of design control recommendations of the Quality System Regulation (21 CFR 820). Risk management activities performed in accordance with ISO 14971did not identify any different risks or risk levels compared to other currently marketed devices.   A list of all anticipated adverse events is listed in th e IFU for each device.  
 
[ADDRESS_1137271]- market, real world, prospective, single- arm, multi-center study looking 
at patients that present with LE ALI who are eligible for mechanical thrombectomy using 
the Indigo Aspi[INVESTIGATOR_228483]. Up to 130 subjects at up to 25 sites globally  will participate.  
 Study Objectives/Endpo ints 
4.2.1 Primary Endpoints  
• Target limb salvage rate at [ADDRESS_1137272]-procedure   
4.2.2 Secondary Endpoints  
• Technical success defined as TIMI 2/[ADDRESS_1137273] -procedure  
• Modified SVS runoff score  immediate post- procedure as compared to 
baseline  
• Improvement of Rutherford classification of one or more as compared to 
the pre- procedure  
• Patency at 1 month 
• Target limb salvage rate at [ADDRESS_1137274]-procedure 
• Rates of device related serious adverse events (SAEs)  
• Major bleeding peri-procedure  
• Mortality at 12 months 
 
5  Study Population  
 Inclusion Criteria  
1. Patient age ≥ 18  
2. Patient presents with acute (≤14 days) occlusion of lower limb artery(ies) 
(below inguinal ligament)  
3. Patient with a Rutherford Category I, IIa or IIb score  
4. Frontline treatment with Indigo Aspi[INVESTIGATOR_228483]  
5. Informed consent is obtained from either patient  or legally authorized 
representative (LAR)  
 
 Exclusion Criteria  
1. Life expectancy <1 year  
2. Target vessel size <2 mm  
3. LE ALI secondary to dissections, vasculitis and/or target vessel trauma  
4. Amputation in the ipsilateral limb  
5. Pregnancy or positive pregnancy test according to site specific standards of care 
(only required for women of childbearing potential, serum or urine acceptable) 
6. Absolute contraindication to contrast administration  
7. Patient is unwilling or unable to comply with protocol follow up schedule and/or based on the Investigator’s judgment the patient is not a good study candidate  
CLP-[ZIP_CODE].D CONFIDENTIAL  Page 15 of 45 
 8. Currently participating in an investigational drug or device clinical trial that 
may confound the study endpoints. Patients in observational, natural history, and/or epi[INVESTIGATOR_820589]. 
9. Target thrombus in a saphenous vein by[CONTACT_9292] 
6 
Study Procedures  
 Overview of Study  Flow  
Patients presenting with LE ALI should be assessed for eligibility. All sites will keep a 
screen failure log of all potential study candidates who are screened and not enrolled or screened, consented, and not enrolled. Reason(s) for  exclusion will be recorded. Screening 
information , including screen failures, will be reported in Electronic Data Capture system 
(EDC).  
Recruitment rates will be tracked over time for each site. The actual recruitment rates will be useful for planning fu rther clinical studies and determining the widespread impact of 
the therapy. 
  
CLP-[ZIP_CODE].D CONFIDENTIAL  Page 16 of 45 
 Figure 1: Study  Flow  
 
 
 
 
  

CLP-[ZIP_CODE].D CONFIDENTIAL  Page 17 of 45 
 
 Study  Visits  
Subjects enrolled in this study will follow the visit schedule below  and will continue to 
receive routine practice/standard of care treatment at each follow up visit. Procedure is 
Day 0  for determining follow up visit dates.   
1. Baseline Evaluation  
2. Procedure (Day 0)  
3. Discharge and/or [ADDRESS_1137275]  
4. 30 Day Follow- Up (± 14 days) 
5. 180 Day  Follow- Up (± 30 days) 
6. 365 Day  Follow- Up (± 60 days) 
 Recruitment  and Screening  
The target population are subjects ≥[ADDRESS_1137276] of care evaluations will be used to confirm eligibility. 
Potential study participants and/or the subjects’ representative (e.g. LAR, next of kin, 
family member, etc.)   will be identified by [CONTACT_820602].   
 Enrollment  
Patients will be considered enrolled once informed consent is obtained per Institutional 
Review Board (IRB)/Ethics Committee (EC), the Indigo Aspi[INVESTIGATOR_820590], and all eligibility is confirmed. Patients who fail to meet entry criteria will be considered a screen fail.  
All follow -up visits will be conducted based on date of procedure, regardless of enrollment 
date.  
 Informed Consent   
The Investigator or designee will obtain written informed consent from the subject or th e 
subjects’ representative (e.g. LAR, next of kin, etc.) using the current Institutional Review 
Board  (IRB)/Ethics Committee ( EC) approved consent form per IRB/EC policy.  
For sites in North America, patients who have had a procedure (using the Indigo Aspi[INVESTIGATOR_820591])  and all eligibility is confirmed, may be consented up to [ADDRESS_1137277] -procedure but prior to initial 
discharge, and enrolled in the study. The point of enrollment is defined as the date of 
informed consent or introduction of the Indigo Aspi[INVESTIGATOR_672211], whichever occurs later.  
For sites in Europe, the informed consent process will be applied per local Ethics Committee approvals . 
All informed consent documents used under this protocol will be consistent with applicable elements of  Good Clinical Practice (ICH E6), ISO [ZIP_CODE],Clinical investigation 
CLP-[ZIP_CODE].D CONFIDENTIAL  Page 18 of 45 
 of medical devices for human subjects – Good Clinical Practice (GCP), FDA  21 CFR Part 
50 Protection of Human Subjects, and  will be approved by [CONTACT_779]’s reviewing IRB/EC  
prior to study initiation.  
Any modification to the sample informed consent form made by [CONTACT_820603] /EC before use. Each study site will provide the 
Sponsor with a copy of the IRB/EC approved consent forms. Informed consent completion 
will be monitored regularly by [CONTACT_1034].  
 Baseline  Evaluation 
Subject s will be clinically evaluated in the same manner as any patient presenting with 
LE ALI. The medical history screen, available clinical exams obtained, and imaging 
information per institutional routine care will be evaluated to determine patient eligibility. Medication , standard of care lab values , and duplex ultrasound will be recorded.  
 Patients will be screened against study eligibility criteria during standard clinical practice. A signed study- specific IRB /EC-approved informed consent form (ICF) must be obtained 
from each potential subject (or th e subjects’ representative (e.g. LAR, n ext of kin, family 
member, etc.) ) before performing any test that goes beyond standard clinical care.  
 These exams  were chosen on the basis of their reliability, familiarity to the endovascular 
community , and comparability to other trials of LE ALI. All s cores will be recorded in 
source documentation and entered into the electronic case report forms (eCRFs).  
 
• Ankle- Brachial Index : ABI is a diagnostic test used to c ompare the systolic 
blood pressure  at the ankle with the systolic blood pressure measured in the 
arm to gauge circulation.  
• Rutherford Classification for LE ALI characterizes the acute presentation of patient clinical symptoms with objective findings, including arterial and venous Doppler signals (see APPENDIX II: Classifications and Scales ). 
• Vascular Quality of Life Questionnaire-6: VascuQoL- 6 is a valid health -
related quality of life questionnaire developed for use in peripheral arterial disease (see APPENDIX II: Classifications and Scales ) 
 
Baseline assessments will be performed , but not limited to  the following: 
1. Demographics 
2. Confirm eligibility  
3. General medical hist ory 
4. Pregnancy test (only required for women of childbearing  potential) 
5. Vital signs 
6. Rutherford C lassification  
7. Ankle- Brachial Index (ABI)  
8. Duplex Ultrasound (DUS) , Computed Tomography Angiography (CTA), 
or Magnetic Resonance Angiography  (MRA): will provide an initial 
diagnosis of LE ALI per institutional routine care  
9. Medication  review  
CLP-[ZIP_CODE].D CONFIDENTIAL  Page [ADDRESS_1137278] of care (SOC)  (most recent 
results obtained within 30 days prior to index procedure are permitted as 
baseline data)  
a. INR, PT, aPTT/ PTT, Platelets,  WBC, RBC, Hgb, Hct, C reatinine, 
Glucose, BUN 
b. Additional SOC labs may be collected, if available  
 Procedure  
All procedures  will be conducted in accordance with standard of care guidelines for 
treatment of patients with  LE ALI at each participating hospi[INVESTIGATOR_307]. The procedure will occur 
after completion of baseline , clinical assessments , and pre -procedural imaging. The Indigo 
Aspi[INVESTIGATOR_820592] A spi[INVESTIGATOR_820593] .  
6.7.[ADDRESS_1137279] of care guidelines at the study site.   6.7.3 Devices and Equipment  
The follow devices/equipment will be used in addition to the standard devices used per site routine standard of care.  
 
Please refer to the device description S ection 2.0 for complete details.  
  
CLP-[ZIP_CODE].D CONFIDENTIAL  Page 21 of 45 
 6.7.4 Index Procedure  
Subjects enrolled in the study should receive the SOC procedural care for LE ALI . 
At a minimum, the following information will be collected during Index Procedure , 
but not limited to : 
1. Initial (pre -procedure)  
a. The following assessments will be administered b efore the 
Indigo Aspi[INVESTIGATOR_820594]:  
• Angiography: p erformed to assess procedure data 
points including the modified SVS runoff score.  
• Modified SVS runoff score: c alculated using the 
angiogram by [CONTACT_820604]/occlusion in the popliteal artery and the three tibial vessels
17  
2. Target lesion characteristics  
3. After Indigo Aspi[INVESTIGATOR_820595]  (which can be considered Final if 
adjunctive procedures are not required) t he following assessments will 
be administered , but not limited to:  
a. Angiography  
b. Modified SVS runoff score  
c. TASC II  score, if applicable  
4. Final (after all adjunctive procedures are complete)  
a. Angiography   
b. Modified SVS runoff score  
5. Procedural details including key procedural timepoints  
6. Adjunctive procedure(s)  
7. Adverse event review  
8. Medication review  
9. Device d eficiencies  
 
Angiography should be uploaded per section 7.5 Image Upload. 
 
6.7.5 Discharge and/or [ADDRESS_1137280]  
Information will be collected during discharge and/ or 7-day visit, (within [ADDRESS_1137281]) , but not limited to the 
following: 
1. Vital signs 
2. Rutherford c lassification  
3. ABI 
4. Adverse event review  
 
In addition to the assessments above , the following will be collected at discharge:  
1. The location that the subject is discharged to and the date of discharge  
2. If any adverse events occurred, it will be reported on the Adverse Event Form  
CLP-[ZIP_CODE].D CONFIDENTIAL  Page [ADDRESS_1137282] was admitted to during the 
index admission will be recorded 
4. Medication use 
6.7.6 30 Day Follow Up Visit (± 14 days) 
Information will be collected during the 30- day follow up visit , but not limited to 
the following: 
1. Vital signs 
2. Rutherford c lassification  
3. DUS, CTA, or MRA 
4. ABI 
5. VascuQoL -6 
6. Medication review  
7. Adverse event  review  
 
6.7.7 180 Day Follow Up Visit (± 30 days) 
Information will be collected during the 180- day follow up visit , but not limited to 
the following: 
1. Vital signs  
2. Rutherford classificat ion 
3. DUS, CTA or MRA 
4. ABI 
5. VascuQoL -6 
6. Medication review  
7. Adverse event review  
6.7.8 365 Day Follow Up Visit (± 60 days) 
Information will be collected during the 365- day follow up visit , but not limited to 
the following: 
1. Vital signs  
2. Rutherford classification  
3. DUS, CTA, or MRA 
4. ABI 
5. VascuQoL -[ADDRESS_1137283] / Ethics Committee Approval 
Prior to enrolling patients into the study, the Investigator will ensure that proper IRB/ EC 
approval is obtained in accordance with applicable local laws and regulations.  The IRB/EC shall approve all study documents as appropriate, including but not limited to the 
final protocol, amendments to the protocol, IFU  (where applicable), and the inf ormed 
consent , per FDA 21 CFR part 56; Institutional Review Boards or applicable EC 
requirements. The investigator should keep the IRB/EC informed of any serious adverse event, or serious device defects as per their policy.  
The Investigator will report to the Sponsor or designee immediately if  the approval to 
conduct the investigation is withdrawn by [CONTACT_1201]/EC or Competent Authority as 
required . The report will include a complete description of the reason(s) for which 
approval was withdrawn.  
 Informed Consent  
The Investigator is responsible for ensuring that completed informed consent is obtained 
in accordance with Section 6.5 of this protocol and according to country and local requirements prior to conducting any study- related assessments prior to  enrollment of 
patients in the study. 
 Adherence to Protocol/Amendments and Applicable Law  
The Investigator is responsible for overseeing, ensuring that the study is conducted, and 
completing the study according to this protocol and in accordance with the relevant aspects of  ISO [ZIP_CODE], 21 CFR 50, 54, and 56, Declaration of Helsinki, along with any 
conditions imposed by [CONTACT_3488]/EC, and all other applicable regulations. The 
Investigator shall approve and adhere to this protocol and any amendment s that arise 
during the course of the study. The Investigator has overall responsibility of the conduct 
of this study including oversight of all delegated individuals, tasks and all activities conducted under this protocol pursuant to FDA 21 CFR part 820 a nd Investigator 
responsibilities.  
It is the Investigator’s responsibility to ensure that the Institution’s staff assisting with the 
study have the appropriate qualifications, are fully instructed on the study procedures, and will respect study confidential ity.  
 Case Report Form Completion  
The Investigator and study staff shall complete the e CRFs associated with this study. 
Subject numbers shall be used to identify individual participants  in this study. The e CRFs 
should be a complete and accurate record of subject data collected during the study according to relevant aspects of ISO [ZIP_CODE], FDA 21 CFR 11, Electronic Records; 
Electronic Signatures  and GCP requirements. It is the Investigator's responsibility to 
ensure the quality of the data collected and recorded is appropriate and collected in 
accordance with GCP and all applicable regulations . Data entry will be performed by [CONTACT_68569](s). Investigators are responsible for completion and timely submission 
CLP-[ZIP_CODE].D CONFIDENTIAL  Page [ADDRESS_1137284]  or study site 
(e.g. Physician name, Institution name, patient name, etc.).  
 Reporting  
The Investigator will be responsible for reporting the following: 
7.6.1 Adverse Events  
Adverse events (AE) must be recorded by [CONTACT_57672] e CRFs and will be 
monitored during the entire study. All SAEs and procedure and device related AE s 
will be collected starting at Day 0  through final follow up for enrolled subjects . 
Additionally, bleeding complications should be reported.  
Minimum requirements of data to be recorded are: event term , event  start date , 
seriousness, action taken, outcome and device- relatedness or causality.  
In order to ensure prompt reporting of AEs, a ll reportable AEs (as well as all related 
study data) are required to be entered i nto the EDC in a timely manner . Any 
suspected Unanticipated Adverse Device Events ( UADEs )/ Unanticipated Serious 
Adverse Device Effects ([LOCATION_003]DE)  should be reported immediately by [CONTACT_820605] . All device related Serious Adverse Events ( SAEs ) should be reported in 
the EDC within [ADDRESS_1137285] report adverse event s to the IRB/EC according to local  
requirements. The Investigator is responsible for r eporting time frames and 
complying with local or national requirements.  In addition, the Investigator will 
report to the sponsor and IRB/EC any device malfunctions that could have led to a 
SAE, if required by [CONTACT_204524]. 
For the purpose of reporting within this protocol, pre -existing conditions or planned 
procedures for pre -existing conditions are not report able as AEs unless there is 
worsening of the condition with an increase in severity or frequency during the 
course of the st udy. All deaths will be reported regardless of causality. When 
reporting a death, the primary condition or diagnosis that contributed to the fatal outcome should be reported as a SAE with an outcom e of death. Only a single cause 
CLP-[ZIP_CODE].D CONFIDENTIAL  Page 26 of 45 
 of death should be reported in EDC. If the cause of death is unknown, repor t 
“unknown cause of death” as a SAE.  
7.6.[ADDRESS_1137286] redacted source documents and review 
adverse events.  
[IP_ADDRESS] Definitions 
• Adverse Event (AE) : Any undesirable clinical event occurring in a patient 
during a clinical trial, whether or not it is considered related to the study  
device or whether anticipated  or unanticipated .  This includes a change in a 
patient's condition or laboratory results that has or could have a deleterious 
effect on the patient's health or well -being or untoward clinical sign in users  
or other persons related to use of medical device.  
• Adverse Device Effect (ADE):  An adverse event  related to the use of the 
study medical device.  
• Definition of SAE   
A SAE is an event that:  
o Led to death  
o Led to a serious deterioration in the health of the patient that: 
− Resulted in life -threatening illness or injury  
− Resulted in chronic disease 
− Resulted in permanent impairment of a body structure or a body function  
− Required in- patient hospi[INVESTIGATOR_4967]  
− Resulted in medical or surgical intervention to arrest permanent impairment to body structure or a body function  
− Led to fetal distress, fetal death or a congenital abnormality or birth defect  
• Unanticipated Adverse Device Event (UADE):  An unanticipated adverse 
device effect is any serious adverse effect on health or safety or any life-threatening problem or death caused by, or associated with, a device, if that effect, problem, or death was not previously identified in nature, severity, or degree of incide nce in the   current risk assessment.   
[IP_ADDRESS] Relationship to the Study Device 
An AE is considered to be device -related when it is reasonable to believe that 
the event may have been caused by [CONTACT_204525]. The f ollowing 
CLP-[ZIP_CODE].D CONFIDENTIAL  Page 27 of 45 
 definitions will be used to assess the relationship of the adverse event to the use 
of study device.  
• Definite:   The temporal sequence is relevant and the event abates upon 
device application completion/removal, or reappearance of the event on 
repeat device application  
• Probab le:  The temporal sequence is relevant or the AE abates upon 
device application completion/removal or the AE cannot be reasonably explained by [CONTACT_423]’s condition or comorbidities.  The AE is related 
or most likely associated with the device  
• Possible:  The temporal sequence between the device and the AE is such 
that the relationship is not unlikely or there is no contradicting evidence that can reasonably explain the subject’s condition.  There is a possibility 
of a relationship between the AE and the de vice 
• Unrelated:   The AE is not associated with the device.   There is no relation 
between the AE and the device  
Similar grading will be used for assessing the relationship to index procedure and to index LE ALI.   
7.6.[ADDRESS_1137287] led to a 
serious adverse event if a) suitable action had not been taken or b) intervention has not be made or c) if cir cumstances had been less fortunate.  
Device manufacturers are required to report qualifying medical device incidents to the relevant national competent authorities. An incident is defined as “any malfunction or deterioration in the characteristics and/or p erformance of a device, 
as well as any inadequacy in the labeling or the instructions for use which, directly or indirectly, might lead to or might have led to the death of a subject or to a serious deterioration in their state of health.” A deterioration in state of health is not considered unanticipated if the condition leading to the event was considered in a risk analysis.  
7.6.4 Protocol Deviation  
Deviations defined in this protocol  should be clearly documented , if identified  
during monitoring or through other means.  For this study, deviations should be 
reported for the following categories:  
CLP-[ZIP_CODE].D CONFIDENTIAL  Page 28 of 45 
 • Inclusion/exclusion criteria  deviation(s) 
• Informed consent deviation(s) 
 Records Retention  
The Investigator shall maintain the records associated with this study for a period as 
defined by [CONTACT_427] A Trial Master File ( TMF ) will be used as the master 
repository for all site and Sponsor regulatory documents. These records include the 
followin g: 
• Correspondence with the Sponsor or designee, the Medical Monitor, and other investigators 
• Subject source records, including but not limited to: Informed Consent Forms, 
copi[INVESTIGATOR_820596] e CRFs, and supporting documents (laboratory reports  and 
reports of diagnostic tests, medical records, etc.) 
• All versions of the study protocol  
• Documentation of protocol deviations  
• Reports of any serious adverse event and  serious adverse device effects , if any 
• A copy of all approvals related to the clinical study 
• The approved, blank, informed consent form  
• All approval/acknowledgment letters from the IRB/EC for all versions of the 
study protocol, ICF and other documents 
• Clinical Trial Agreement (s) 
• Signed and dated curriculum vitae for all study personnel  
• Medical licenses or equivalent for the Principal Investigator [INVESTIGATOR_820597]-Investigators 
• Financial disclosure for the Principal Investigator [INVESTIGATOR_204499]-
Investigators  
• All required regulatory documents such as Delegation of Authority and training logs 
• Signed Protocol Signature [CONTACT_3490](s)  
• Data Privacy Agreements for the Principal Inve stigator and all hospi[INVESTIGATOR_820598] (EU sites only) 
• Product liability certificates (EU sites only)  
[ADDRESS_1137288] of the names  and addresses of the clinical investigators for 
the study, including the investigator role and his specialty . 
 
CLP-[ZIP_CODE].D CONFIDENTIAL  Page 29 of 45 
 
 Adverse Event Reporting  
The Sponsor shall evaluate adverse event reports received from the study sites and found 
during data monitoring and shall report them to the appropriate regulatory bodies and other study sites as necessary.  
 Data Monitoring 
Penumbra is responsible for ensuring that the study is conducted according to applicable portions of the regulations (US Food and Drug Administration 21 CFR 812, ISO [ZIP_CODE]). A Penumbra employee or designate will conduct the following site visits:  
8.4.[ADDRESS_1137289] information and study data centrally via a web browser.  
Automated data quality checks will display warnings for invalid data. Additionally, 
manual review of data listings may be used to identify data discrepancies or inconsistencies. The study site may be queried for clarification concerning e CRF  
discrepancies or inconsistencies identified. If eCRF  corrections are necessary , they will 
be made by [CONTACT_204527]'s staff that is delegated to eCRF/EDC. Questions or problems with submitted data will be addressed 
with the Principal Investigator [INVESTIGATOR_204500], or through direct contact. The Investiga tor will review the e CRF s for completeness and accuracy and 
provide his/her electronic signature [CONTACT_820610] e CRF s as evidence thereof. Any data items 
that have been changed will require reapplication of the electronic signature. 
Study personnel will have individual login and password to access the clinical study 
information based upon each individual’s roles and responsibilities. The application provides hierarchical user permission data entry, viewing, and reporting options. 
All data entry and data update information, including the date and person performing the 
action, will be available via the audit trail, which is part of the EDC system.  
All eCRF s and data files will be secured to ensure confidentiality. Investigators are 
required to maintain source documents required by [CONTACT_760], including laboratory 
results, reports, supporting medical records, and Informed Consent Forms. The source documents will be used during the regular monitoring visits to verify information entered on the e CRF s. 
9 
Ethical Requirements  
 Declaration of Helsinki 
The study will be performed in accordance with the applicable aspects of ISO [ZIP_CODE], 
recommendations guiding physicians in biomedical research involving human subjects adopted by [CONTACT_941] 18th World Medical Assembly, Helsinki, Finland (1964 and later revisions), ICH and US FDA GCP guidelines. 
It is the responsibility of the Investigator to obtain approval of the study protocol from the 
IRB/EC and to keep the IRB/EC informed of any serious adverse event, serious adverse 
device effects, and amendments to the protocol. All correspondence with the IRB/EC  
should be filed by [CONTACT_187641][INVESTIGATOR_204501].
 
 Informed Consent  
The Investigator is responsible for ensuring that a completed  informed consent is obtained 
in accordance with Section 6.[ADDRESS_1137290]’s name [CONTACT_820611]. All e CRFs will be tracked, evaluated, and stored using only the 
subject ID number. No personal identifying information will be included on the eCRFs . 
The informed conse nt fo rm wi ll notify subjec ts that study monitors, Sponsor’s 
representatives, auditors, a nd r eprese ntatives of  government agenc ies and ethics 
committees will have access to pe rsonal ident ifying infor mation to ensure  that data  
reporte d on the eCRF s corresponds t o the per son who si gned the  conse nt fo rm and the 
information contained in the source docu ment ation. 
Each subject must be informed that the data collected will be stored and analyzed by [CONTACT_820606]. Furthermore, each subject should be informed about the possibility of inspection of relevant parts of the hospi[INVESTIGATOR_204502], or other Health Authorities, including the FDA; and that the data will be electronically stored in the [LOCATION_002].  
[ADDRESS_1137291] deviation, inter -quartile range, minimum 
and maximum for continuous variables and counts and percent ages for discrete variables. 
Analyses will be conducted using SAS (SAS Institute, Cary, NC). The specific details of 
the planned analyses are described completely in the statistical analysis plan.  
 Sample Size Estimation for the Primary Outcome 
The sample size calculations assume that 94% ( 108/115) of the study subjects achieve 
target limb salvage [ADDRESS_1137292] -procedure as compared to 95.7% patients undergoing 
current standard of care treatments. Based on a binomial analysis with a non -inferiority 
margin of 10%, a study of [ADDRESS_1137293] 80% power with a one -sided 
alpha of 0.025. The sample size was adjusted to 130  subjects  to account for approximately 
10% attrition.  
 Control of Systematic Error and Bias 
The study will be conducted under a common protocol for each study s ite with the intention 
of pooling the data for analysis. Every effort will be made to promote consistency in study execution at each study site.  
 Missing Data and Imputation Methods  
Every effort will be made to keep al l miss ing data, particularly at the 30- day follow -up 
visit, to a minimum. S ome data may be missing,  mainly due to lost -to-follow- up (LTFU)  
CLP-[ZIP_CODE].D CONFIDENTIAL  Page [ADDRESS_1137294] metric will be provided for 365 -day follow -
up. 
 Definition of Analysis Populations 
10.6.1  Intent to Treat Sample  
As the primary analysis, all performance and safety outcome measures will be 
analyzed under the intent -to-treat (ITT) principle. Under this principle, the ITT 
sample includes all subjects who are enrolled. This population is the primary 
analysis population.   
 Interim Analysis  
No interim analyses are planned for the purpose of terminating the study for a positive 
result. Interim analysis without hypothesis testing may be performed for regulatory 
submission or publication of study results.  No adjustments will be made to the confidence 
bounds for the final analysis.  
CLP-[ZIP_CODE].D CONFIDENTIAL  Page [ADDRESS_1137295] -procedure. The 
primary safety analysis will be the difference between the study group and the combined 
historical control rate of 95.7% observed under current standards of care. 
The null hypothesis is that the difference between the primary endpoint rate and the 
standard of care at [ADDRESS_1137296] -procedure is less  than or equal to -10%. The alternative 
hypothesis is the difference at [ADDRESS_1137297]-procedure is greater  than -10%. Formally, the 
null and alternative hypotheses to be tested are as follows: H
0:  P study – 0.957 ≤ - 0.10 
HA:  P study – 0.957 > - 0.[ADDRESS_1137298] -
procedure. The primary safety endpoint is met if the lower  limit of the 95% confidence interval of the 
primary endpoint rate is greater  than 85.7%. The primary  safety  analysis will be 
unadjusted.   
 Secondary Statistical Analysis 
The secondary performance and safety endpoints will be assessed via proportions based on 
the endpoint criteria and 95% confidence intervals will be presented. The modified SVS 
runoff s core will be analyzed both as a categorical and a continuous outcome. Su rvival 
estimates will also be utilized  to evaluate the time -to-event  using K aplan -Meier 
methodology for events through [ADDRESS_1137299] reporting the results will be prepared and 
may be presented at a major meeting(s). A multi- center publication may also be prepared 
for publication in a reputable scientific journal. The publication of results from any single center experience within the study is not allowed until the aggregate study results have 
been published, unless there is written consent from the Sponsor. 
11 
Study Committees and Core Labs   
 Imaging Core Lab 
The Imaging Core Lab is composed of independent medical doctor(s) who are not participants in the study. The Imaging Core Lab is responsible for assisting in the development of specific criteria used for the categorization of clinical endpoints in the study. A web- based electronic database will be provided for the Imaging Core Lab to 
review and adjudicate images. Additional details related to the core lab are specified in the Imaging Core Lab Charter 
The independent imaging core lab will review images from the pre -procedure and post -
procedure (pseudonymized) angi ograms to determine at minimum, the TIMI scores. An 
Imaging core lab charter will provide procedures for core lab review.  
12 
Study Administration  
 Stoppi[INVESTIGATOR_820599]. The s tudy 
can be temporarily suspended to evaluate any negative safety trends.  
 Clinical Study Termination/Withdrawal 
Subjects may be terminated or withdrawn from the study for the following reasons: 
• Voluntary withdrawal of consent –– meaning that a subject voluntarily chooses 
not to participate further in the study.  All data collected up to the withdrawal of 
consent will be maintained in the study database.  Withdra wn subj ects wi ll not  
have any addit ional follow-up an d will not be re placed. 
• Lost to follow-up –– a subject will be considered lost- to-follow-up when contact 
[CONTACT_820607]- up vi sit window .  At a minimum, the 
effort to obtain follow -up information will include three (3) attempts to make 
contact [CONTACT_204530] e -mail and if unsuccessful, then a letter from the 
Investigator sent via courier or other traceable method will be sent to the subj ect’s 
last known address. These efforts to obtain follow -up will be recorded in the 
subject’s  study files. 
• Subjects may also be withdrawn at the I nvestigator’s discretion if within their 
best interest. A subj ect’s  participation i n the clinical study will be terminate d if 
the Investigator believes that th is is in the subj ect’s b est medica l inte rest or if the 
subject no longe r complies with the clinical stu dy require ments.  
CLP-[ZIP_CODE].D CONFIDENTIAL  Page 35 of 45 
 The sponsor may temporarily suspend or prematurely terminate the study at any time for 
the following reasons: 
• Suspi[INVESTIGATOR_78697] 
• If no positive IRB/EC decision is obtained or if the judgement of the IRB/EC is 
revoked 
• If the applicable regulatory body has made an irrevocable objection 
• If it transpi[INVESTIGATOR_204503], and 
this is confirmed by [CONTACT_1201]/EC  
• Business reasons  
The Sponsor will document reasons for study suspension or premature termination and notify the PIs. The Sponsor will ensure that the IRB/ECs and regulatory authorities are 
notified in a timely manner.  
The Sponsor will conti nue to provide r esources to ful fil the obl igations f rom the study 
protocol and ex isting agreements for follo wing up the subj ects enrolled in t he stu dy. 
The Principal Inve stigato rs will prompt ly inform the enrolle d subj ects at his/her site , 
if appropri ate. 
If the Sponsor tempora rily suspends the study a nd wish es to r esume it, the Sponsor will 
inform the PIs, IRB/ECs, a nd (if  appropri ate) regulato ry authorities.  T he Sponsor will 
provide a rat ionale for resumin g the s tudy.  IRB/EC s mu st provide w ritten approva l 
before the s tudy is resumed. 
 Missing Visits  
Every effort should be made to bring subject in to scheduled follow -up visits. Any study 
subject who does not attend a scheduled follow -up visit should be contact[CONTACT_820608].  If the missed visit was due to a n adverse event , an AE eCRF must 
be completed and any reporting requirements met.  
 Protocol Adherence and Amendments  
Prior to beginning the study, the Principal Investigator [INVESTIGATOR_820600]/her agreement to conduct the study in accordance with this protocol. Deviations outlined in section 7.6.[ADDRESS_1137300] be documented and reported to Penumbra as soon as possible, and to the IRB/EC per local guidelines and government regulations. 
 Study Registration 
The study will be registered in a publicly accessible trial study database (e.g., clinical trials.gov) prior to study initiation. 
[ADDRESS_1137301] device and research, including patent applications, manufacturing processes, basic scientific data, etc., is considered confidential and should remain the sole property of Penumbra.  The Investigator agrees to use t his information only 
in connection with this study and will not use it for other purposes without written permission from the Sponsor. 
  
CLP-[ZIP_CODE].D CONFIDENTIAL  Page 38 of 45 
 15  References  
1. Gilliland, C., Shah, J., Martin, J.G., and Miller, M.J., Jr. (2017). Acute limb ischemia. 
Tech Vasc Interv Radiol . 20(4): p. 274-280. 
2. Gerhard -Herman, M.D., Gornik, H.L., Barrett, C., Barshes, N.R., Corriere, M.A., 
Drachman, D.E., . . . Walsh, M.E. (2017). 2016 aha/acc guideline on the management of 
patients with lower extremity peripheral artery disease: A report of the american college of cardiology/american heart association task force on clinical practice guidelines. J Am Coll Cardiol . 69(11): p. e71-e126. 
3. Aboyans, V., Ricco, J.B., Bartelink, M.E.L., Bjorck, M., Brodmann, M., Cohnert, T., . . . 
Zamorano, J.L. (2018). Editor's choice - 2017 esc guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the europe an society for 
vascular surgery (esvs). Eur J Vasc Endovasc Surg. 55(3): p. 305-368. 
4. Howard, D.P., Banerjee, A., Fairhead, J.F., Hands, L., Silver, L.E., and Rothwell, P.M. 
(2015). Population-based study of incidence, risk factors, outcome, and prognosi s of 
ischemic peripheral arterial events: Implications for prevention. Circulation . 132(19): p. 
1805-15. 
5. Baril, D.T., Ghosh, K., and Rosen, A.B. (2014). Trends in the incidence, treatment, and 
outcomes of acute lower extremity ischemia in the united sta tes medicare population. J 
Vasc Surg. 60(3): p. 669-77 e2. 
6. Acar, R.D., Sahin, M., and Kirma, C. (2013). One of the most urgent vascular 
circumstances: Acute limb ischemia. SAGE Open Med. 1: p. 2050312113516110. 
7. Creager, M.A., Kaufman, J.A., and Conte, M.S. (2012). Clinical practice. Acute limb 
ischemia. N Engl J Med . 366(23): p. 2198-206. 
8. Rutherford, R.B., Baker, J.D., Ernst, C., Johnston, K.W., Porter, J.M., Ahn, S., and Jones, 
D.N. (1997). Recommended standards for reports dealing with lower extr emity ischemia: 
Revised version. J Vasc Surg. 26(3): p. 517-38. 
9. Leung, D.A., Blitz, L.R., Nelson, T., Amin, A., Soukas, P.A., Nanjundappa, A., . . . 
Simoni, E.J. (2015). Rheolytic pharmacomechanical thrombectomy for the management of acute limb ischemia: Results from the pearl registry. J Endovasc Ther . 22(4): p. 546-
57. 
10. Investigators, T.S. (1994). Results of a prospective randomized trial evaluating surgery 
versus thrombolysis for ischemia of the lower extremity. The stile trial. Ann Surg. 220(3): p. 251-66; discussion 266-8. 
11. Ouriel, K., Shortell, C.K., DeWeese, J.A., Green, R.M., Francis, C.W., Azodo, M.V., . . . 
Marder, V.J. (1994). A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg. 19(6): p. 1021-30. 
12. Ouriel, K. , Veith, F.J., and Sasahara, A.A. (1996). Thrombolysis or peripheral arterial 
surgery: Phase i results. Topas investigators. J Vasc Surg . 23(1): p. 64-73; discussion 74-
5. 
13. Morrison, H.L. (2006). Catheter-directed thrombolysis for acute limb ischemia. Semin 
Intervent Radiol . 23(3): p. 258-69. 
14. Shishehbor, M.H. (2014). Acute and critical limb ischemia: When time is limb. Cleve 
Clin J Med . 81(4): p. 209-16. 
CLP-[ZIP_CODE].D CONFIDENTIAL  Page 39 of 45 
 15. Kwok, C.H.R., Fleming, S., Chan, K.K.C., Tibballs, J., Samuelson, S., Ferguson, J., . . . 
Jansen, S.J. (2018). Aspi[INVESTIGATOR_820601]- directed 
thrombolysis as first- line treatment for noniatrogenic acute lower limb ischemia. J Vasc 
Interv Radiol . 29(5): p. 607-613. 
16. Saxon, R.R., Benenati, J.F., Teigen, C., Adams, G.L., Sewall, L.E., and Trialists, P. 
(2018). Utility of a power aspi[INVESTIGATOR_1516]-based extraction technique as an initial and 
secondary approach in the treatment of peripheral arterial thromboembolism: Results of the multicenter prism trial. J Vasc Interv Radio l. 29(1): p. 92-100. 
17. Duval, S., Keo, H.H., Oldenburg, N.C., Baumgartner, I., Jaff, M.R., Peacock, J.M., . . . 
Hirsch, A.T. (2014). The impact of prolonged lower limb ischemia on amputation, mortality, and functional status: The friends registry. Am Hea rt J. 168(4): p. 577-87. 
18. Hardman, R.L., Jazaeri, O., Yi, J., Smith, M., and Gupta, R. (2014). Overview of 
classification systems in peripheral artery disease. Semin Intervent Radiol . 31(4): p. 378-
88. 
19. Surgery, T.W.G.a.t.S.f.V. (2000). Clinical clas sification of acute limb ischemia. J of Vasc 
Surg. 31(1): p. S142-S145. 
20. Stoner, M.C., Calligaro, K.D., Chaer, R.A., Dietzek, A.M., Farber, A., Guzman, R.J., . . . 
Society for Vascular, S. (2016). Reporting standards of the society for vascular surgery for endovascular treatment of chronic lower extremity peripheral artery disease. J Vasc Surg. 64(1): p. e1-e21. 
21. Sarkar, A., Grigg, W.S., and Lee, J.J., Timi grade flow, in Statpearls. 2020: Treasure 
Island (FL).  
22. Nordanstig, J., Wann-Hansson, C., Karlsson, J., Lundstrom, M., Pettersson, M., and 
Morgan, M.B. (2014). Vascular quality of life questionnaire- 6 facilitates health -related 
quality of life assessment in peripheral arterial disease. J Vasc Surg. 59(3): p. 700-7. 
   
CLP-[ZIP_CODE].D CONFIDENTIAL  Page 40 of 45 
 16 APPENDIX I : Definitions and Classifications  
 Definitions  
Acute Limb Ischemia:  Acute (≤14 days), severe hypoperfusion of the limb 
characterized by [CONTACT_314580]: pain, pallor, pulselessness, 
poikilothermia (cold), paresthesias, and paralysis.2 
Amputation :  The complete or partial removal of lower limb or extremity.  
Minor amputation is surgical removal of a portion or segment of the lower extremity distal or through the 
tarso meta tarsal joints.  
Major amputation is complete or partial removal that occurs proximal to the tarsom etatarsal joints.
22  
Limb Salvage:  Condition of extremity with potential to secure viability and 
preserve motor function to the weight-bearing portion of the foot if treated.
2 
Limb is considered salvagable if amputation is performed  at or distal to tarsal/metatarsal joint.
22 
Major Bleeding:  Fatal or leading to a drop in hemoglobin of ≥5 g/dl, or 
significant hypotension with the need for inotropes, or requiring surgery (other than vascular site repair), or symptomatic intracranial hemorrhage (ICH), or requiring transfusion of two or three units of red blood cells or 
equivalent whole blood.   
Minor Bleeding:  Bleeding that result s in a drop in  hemoglobin  3 to <5 g/dL 
and/or that require s a blood transfusion of 1 unit of red blood 
cells or equivalent whole blood. 
Modified SVS Runoff  Score : Calculated using the angiogram by [CONTACT_820609]/occlusion in the popliteal artery and the 
three tibial vessels.17  
Nonviable Limb:  Condition of extremity (or portion of extremity) in which 
loss of motor function, neurological function, and tissue integrity cannot be restored with treatment.
2 
Patency:  Patency is defined as a target lesion without a 
hemodynamically significant stenosis/reocclusion on duplex ultrasound (>50%,) and without target lesion reintervention (TLR).
 
TransAtlantic Inter -Society 
Consensus for the Management of Peripheral Arterial Disease (TASC II)  
Score  Used to classify vessel or arterial disease severity in the 
aortoiliac and femoropopliteal segments . 
CLP-[ZIP_CODE].D CONFIDENTIAL  Page [ADDRESS_1137302]  Aspi[INVESTIGATOR_1516] –Based Extraction Technique  
  